Latest news with #Genelux
Globe and Mail
16-07-2025
- Business
- Globe and Mail
Oncolytic Virus Cancer Therapy Pipeline Appears Robust With 120+ Key Pharma Companies Actively Working in the Therapeutics Segment
DelveInsight's, 'Oncolytic Virus Cancer Therapy Pipeline Insight, 2025,' report provides comprehensive insights about 120+ companies and 125+ pipeline drugs in Oncolytic Virus Cancer Therapy pipeline landscape. It covers the Oncolytic Virus Cancer Therapy pipeline drug profiles, including clinical and non-clinical stage products. It also covers the Oncolytic Virus Cancer Therapy pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Explore our latest breakthroughs in Oncolytic Virus Cancer Therapy Research. Learn more about our innovative pipeline today! @ Oncolytic Virus Cancer Therapy Pipeline Outlook Key Takeaways from the Oncolytic Virus Cancer Therapy Pipeline Report In June 2025, Replimune Inc. conducted a study is to evaluate whether treatment with RP2 can provide efficacy as 2L treatment combined with atezolizumab plus bevacizumab in patients with locally advanced unresectable, recurrent, and/or metastatic HCC. DelveInsight's Oncolytic Virus Cancer Therapy pipeline report depicts a robust space with 120+ active players working to develop 125+ pipeline therapies for Oncolytic Virus Cancer Therapy treatment. The leading Oncolytic Virus Cancer Therapy Companies such as Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Oncolys BioPharma, Turnstone Biologics and others. Promising Oncolytic Virus Cancer Therapy Pipeline Therapies such as Gemcitabine, Valacyclovir, CG0070, Keytruda, atezolizumab, Ipilimumab, TBI-1401(HF10), Bevacizumab, Sorafenib, Pembrolizumab, Talimogene Laherparepvec and others. Stay informed about the cutting-edge advancements in Oncolytic Virus Cancer Therapy treatments. Download for updates and be a part of the revolution in Oncology Care @ Oncolytic Virus Cancer Therapy Clinical Trials Assessment Oncolytic Virus Cancer Therapy Emerging Drugs Profile Olvi-Vec: Genelux Corporation Olvi-Vec is a proprietary, non-pathogenic oncolytic vaccinia virus, modified to increase its safety, tumor selectivity and anti-tumor activity. Virus-mediated oncolysis results in immunogenic cell death and triggers immune activation and memory for long-term immunotherapy against cancer. Clinical results in more than 150 subjects have shown Olvi-Vec is well tolerated with documented clinical benefits. Currently the product is in Phase III stage of development for the treatment of Platinum-Resistant/Refractory Ovarian Cancer CAN-2409: Candel Therapeutics CAN-2409 (aglatimagene besadenovec) is an adenovirus-based replication deficient engineered gene construct encoding the thymidine kinase gene derived from the herpes simplex virus. It is injected directly into the tumor or target tissue The prodrug-derived cytotoxic nucleotide analogs are designed to inhibit DNA replication and repair, leading to the death of multiplying tumor cells, and in particular of cells undergoing repair from radiation or chemotherapy damage. Currently the product is in Phase III stage of development for the treatment of Prostrate Cancer. CG0070: CG Oncology CG0070 is an investigational oncolytic immunotherapy based on a modified common cold adenovirus backbone that contains a cancer-specific promoter and a GM-CSF transgene. CG0070, first replicates inside the tumor's cells causing tumor cell lysis and immunogenic cell death. Then, the rupture of the cancer cells can release tumor-derived antigens, along with GM-CSF, that can stimulate a systemic anti-tumor immune response that involves the body's own white blood cells. CG0070 is in development for a variety of solid tumor types to be used alone or in combination with immune checkpoint modulators. The therapy is in clinical development for the treatment of Bladder cancer and preclinical studies for solid tumors. In advanced clinical studies, CG0070 has been shown to be a safe and efficacious agent in NMIBC following BCG failure. Currently the product is in Phase III stage of development for the treatment of Non Muscular Invasive Bladder Cancer. Pelareorep: Oncolytics Biotech Pelareorep, is an investigational drug being developed by Oncolytics Biotech. It is an intravenously delivered immunotherapeutic agent. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype -- turning "cold" tumors "hot" -- through innate and adaptive immune responses to treat a variety of cancers. Pelareorep has demonstrated synergies with immune checkpoint inhibitors and may also be synergistic with other approved oncology treatments. Currently the drug is being investigated in Phase III stage of Clinical trial evaluation for the treatment of Metastatic Breast Cancer. ParvOryx: Oryx GmbH ParvOryx is an oncolytic parvovirus H1 (H-1PV), a wild type rat virus that infects and lyses tumor cells from a wide variety of cancers. These tumor types include glioblastoma multiforme, pancreatic cancer, breast cancer, lung cancer, melanoma, lymphoma, pediatric tumors such as neuroblastoma and medulloblastoma, prostate cancer and renal cancer, as well as tumor stem cells. H-1PV acts at relatively low multiplicities of infection. The virus exerts both cytotoxic and oncolytic (replication) effects. The cytotoxic effect is predominantly mediated by the non-structural protein (NS1), resulting in cell transcription dysregulation, cell cycle arrest, cell replication shut off, and activation of cellular stress response and induction of cell death. In addition, viral oncolysis induces a strong tumor-specific immune response leading to the recognition and elimination of minimal residual disease (bystander effect). ParvOryx is the smallest of all oncolytic viruses and is able to cross the blood brain barrier. Unlike other natural or modified oncolytic viruses currently under investigation, ParvOryx does not affect normal cells and is not pathogenic to humans. Currently the product is in Phase II stage of development for the treatment of pancreatic cancer. SND005: Jiangsu Sinorda Biomedicine SND005 Oncolytic virus is a type of virus that preferentially infects and kills tumor cells. Initially, some tumor cells were specifically infected and destroyed by oncolytic viruses. Subsequently, the oncolytic virus replicates and proliferates in tumor cells, releasing new infectious virus particles to infect and destroy other tumor cells. Oncolytic viruses exert their oncolytic effects by directly lysing tumor cells or stimulating the host to produce an anti-tumor immune response. Among the new oncolytic virus drugs currently underway, SND005 is the only wild-type virus without genetic modification. It has a 14 - year history of clinical use. In a trial of 540 patients with melanoma, more than 44% of the patients benefited. In the safety and tolerability study of 190 patients, no serious adverse events were found, and the most common adverse event was low-grade fever. The clinical data and observations after the overseas market show that the survival rate of patients is increased by 4- 5 times, and it has excellent performance in stage II melanoma patients. VCN-01: VCN Biosciences VCN-01 is an innovativeconditionally replicative oncolytic adenovirus expressing PH20 hyaluronidase. Expression of hyaluronidase from VCN-01 facilitates virus penetration and decreases intratumorfluid pressure, enhancing antibodyup-take. In addition, VCN-01 capsid has been modified to allow the virus to partially evade liver tropism and target selectively the tumor after intravenous administration. Currently the product is in Phase I stage of development for the treatment of Pancreatic, Serous Epithelial Ovarian Cancer and Squamous Cell of Head and Neck. The Oncolytic Virus Cancer Therapy Pipeline Report provides insights into The report provides detailed insights about companies that are developing therapies for the treatment of Oncolytic Virus Cancer Therapy with aggregate therapies developed by each company for the same. It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Oncolytic Virus Cancer Therapy Treatment. Oncolytic Virus Cancer Therapy Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Oncolytic Virus Cancer Therapy Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Oncolytic Virus Cancer Therapy market. Learn more about Oncolytic Virus Cancer Therapy Drugs opportunities in our groundbreaking Oncolytic Virus Cancer Therapy research and development projects @ Oncolytic Virus Cancer Therapy Unmet Needs Oncolytic Virus Cancer Therapy Companies Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Oncolys BioPharma, Turnstone Biologics and others. Oncolytic Virus Cancer Therapy pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as Intranasal Intravenous Oral Oral/Intravenous Parenteral Subcutaneous Subcutaneous/Intramuscular Oncolytic Virus Cancer Therapy Products have been categorized under various Molecule types such as Oncolytic Virus Discover the latest advancements in Oncolytic Virus Cancer Therapy treatment by visiting our website. Stay informed about how we're transforming the future of Oncology @ Oncolytic Virus Cancer Therapy Market Drivers and Barriers, and Future Perspectives Scope of the Oncolytic Virus Cancer Therapy Pipeline Report Coverage- Global Oncolytic Virus Cancer Therapy Companies- Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Elicera Therapeutics, Orgenesis, Replimune, Immvira Pharma, ViroCure, GeneMedicine, PsiOxus Therapeutics, Vyriad, VCN Biosciences, Beijing Syngentech, Oncolys BioPharma, Turnstone Biologics and others. Oncolytic Virus Cancer Therapy Pipeline Therapies- Gemcitabine, Valacyclovir, CG0070, Keytruda, atezolizumab, Ipilimumab, TBI-1401(HF10), Bevacizumab, Sorafenib, Pembrolizumab, Talimogene Laherparepvec and others. Oncolytic Virus Cancer Therapy Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination Oncolytic Virus Cancer Therapy Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III For a detailed overview of our latest research findings and future plans, read the full details of Oncolytic Virus Cancer Therapy Pipeline on our website @ Oncolytic Virus Cancer Therapy Emerging Drugs and Companies Table of Contents Introduction Executive Summary Oncolytic Virus Cancer Therapy: Overview Pipeline Therapeutics Therapeutic Assessment Oncolytic Virus Cancer Therapy– DelveInsight's Analytical Perspective Late Stage Products (Phase III) Olvi-Vec: Genelux Corporation Mid Stage Products (Phase II) SND005: Jiangsu Sinorda Biomedicine Early Stage Products (Phase I/II) AloCelyvir: Orgenesis Early Stage Products (Phase I) VCN-01: VCN Biosciences Preclinical and Discovery Stage Products SynOV 1.3: Beijing Syngentech Inactive Products Oncolytic Virus Cancer Therapy Key Companies Oncolytic Virus Cancer Therapy Key Products Oncolytic Virus Cancer Therapy- Unmet Needs Oncolytic Virus Cancer Therapy- Market Drivers and Barriers Oncolytic Virus Cancer Therapy- Future Perspectives and Conclusion Oncolytic Virus Cancer Therapy Analyst Views Oncolytic Virus Cancer Therapy Key Companies Appendix About Us DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Yash Bhardwaj Email: Send Email Phone: 09650213330 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
Yahoo
16-06-2025
- Business
- Yahoo
June 2025's Promising Penny Stocks For Savvy Investors
As the U.S. markets navigate a landscape marked by geopolitical tensions and fluctuating oil prices, investors are keenly observing shifts in major indices like the Dow Jones and S&P 500. For those interested in exploring beyond established giants, penny stocks—often representing smaller or emerging companies—remain an intriguing investment area despite their somewhat outdated moniker. By focusing on financially robust penny stocks, investors can uncover potential opportunities that balance risk with promising growth prospects. Name Share Price Market Cap Financial Health Rating Imperial Petroleum (IMPP) $3.37 $115.98M ★★★★★★ New Horizon Aircraft (HOVR) $1.87 $58.69M ★★★★★★ Waterdrop (WDH) $1.34 $484.63M ★★★★★★ Greenland Technologies Holding (GTEC) $2.00 $34.79M ★★★★★★ WM Technology (MAPS) $1.02 $171.54M ★★★★★★ Perfect (PERF) $1.82 $185.36M ★★★★★★ Flexible Solutions International (FSI) $4.25 $53.75M ★★★★★★ BAB (BABB) $0.84 $6.1M ★★★★★★ Lifetime Brands (LCUT) $3.71 $83.16M ★★★★★☆ TETRA Technologies (TTI) $3.48 $463.09M ★★★★☆☆ Click here to see the full list of 724 stocks from our US Penny Stocks screener. Underneath we present a selection of stocks filtered out by our screen. Simply Wall St Financial Health Rating: ★★★★★★ Overview: Genelux Corporation is a clinical-stage biopharmaceutical company specializing in the development of oncolytic viral immunotherapies for challenging solid tumors, with a market cap of $114.14 million. Operations: Genelux Corporation has not reported any revenue segments. Market Cap: $114.14M Genelux Corporation, a clinical-stage biopharmaceutical company with a market cap of US$114.14 million, remains pre-revenue with no substantial revenue streams reported. Despite having sufficient cash runway for over a year and being debt-free, the company faces significant challenges including recent auditor doubts about its ability to continue as a going concern. The stock has experienced high volatility and significant insider selling recently. Genelux's most advanced product candidate, Olvi-Vec, is undergoing multiple trials but the company remains unprofitable with losses increasing by 25.6% annually over the past five years. Jump into the full analysis health report here for a deeper understanding of Genelux. Learn about Genelux's future growth trajectory here. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Quince Therapeutics, Inc. is a biopharmaceutical company dedicated to acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases, with a market cap of $65.02 million. Operations: Quince Therapeutics, Inc. does not have any reported revenue segments. Market Cap: $65.02M Quince Therapeutics, Inc., with a market cap of US$65.02 million, is pre-revenue and currently unprofitable. Despite reducing losses by 11.1% annually over five years, the company faces financial challenges as short-term assets do not cover long-term liabilities of US$80.2 million. Recently, Quince raised over US$11 million through private placements to extend its cash runway beyond 11 months. The company is progressing in its Phase 3 NEAT trial for Ataxia-Telangiectasia treatment with plans to submit an NDA in 2026 if results are positive, though auditor doubts about its going concern status persist amidst high volatility and increased debt levels. Get an in-depth perspective on Quince Therapeutics' performance by reading our balance sheet health report here. Evaluate Quince Therapeutics' prospects by accessing our earnings growth report. Simply Wall St Financial Health Rating: ★★★★☆☆ Overview: Safe Bulkers, Inc., along with its subsidiaries, offers marine drybulk transportation services on an international scale and has a market cap of $396.96 million. Operations: The company generates revenue of $290.31 million from its marine drybulk transportation services. Market Cap: $396.96M Safe Bulkers, Inc., with a market cap of US$396.96 million, operates within the marine drybulk transportation sector. Despite experiencing a decline in earnings growth over the past year, the company has demonstrated financial resilience by reducing its debt-to-equity ratio from 127.9% to 62.9% over five years and maintaining strong operating cash flow coverage of its debt at 23.9%. Recent activities include completing a share buyback program worth US$10.72 million and declaring dividends on both common and preferred shares, reflecting management's commitment to returning value to shareholders despite facing revenue challenges in Q1 2025 compared to the prior year. Click here to discover the nuances of Safe Bulkers with our detailed analytical financial health report. Assess Safe Bulkers' future earnings estimates with our detailed growth reports. Discover the full array of 724 US Penny Stocks right here. Curious About Other Options? We've found 20 US stocks that are forecast to pay a dividend yeild of over 6% next year. See the full list for free. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include GNLX QNCX and SB. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@
Yahoo
30-03-2025
- Business
- Yahoo
Genelux Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Net loss: US$29.9m (loss widened by 5.6% from FY 2023). US$0.95 loss per share. All figures shown in the chart above are for the trailing 12 month (TTM) period Revenue exceeded analyst estimates by 67%. Earnings per share (EPS) missed analyst estimates by 8.6%. Looking ahead, revenue is forecast to grow 64% p.a. on average during the next 3 years, compared to a 20% growth forecast for the Biotechs industry in the US. Performance of the American Biotechs industry. The company's shares are down 22% from a week ago. Be aware that Genelux is showing 4 warning signs in our investment analysis and 2 of those are a bit concerning... Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Sign in to access your portfolio
